Raxar Side Effects
Generic Name: grepafloxacin
Note: This document contains side effect information about grepafloxacin. Some of the dosage forms listed on this page may not apply to the brand name Raxar.
Applies to grepafloxacin: oral tablet
Percentages below refer to patients treated on multiple-dose regimens.[Ref]
Nausea and taste perversion (e.g. medicinal taste) are the most common adverse effects of grepafloxacin (the active ingredient contained in Raxar) occurring in as many as 11% to 16%, and 9% to 18% of patients, respectively. Other gastrointestinal effects including diarrhea, abdominal pain, vomiting, dyspepsia, anorexia, dry mouth, and constipation have been reported in 1% to 4% of patients. Abnormal stools, cheilitis, dysphagia, eructation, flatulence, gastritis, gastrointestinal disorder, gingivitis, glossitis, increased appetite, melena, mouth ulceration, oral moniliasis, rectal disorder, rectal hemorrhage, stomatitis, tenesmus, thirst, tongue discoloration, tongue disorder, and tongue edema have been reported in less than 1% of patients.[Ref]
Nervous system side effects have included headache, dizziness, insomnia, somnolence, and nervousness in 1% to 5% of patients. Abnormal dreams, abnormal gait, agitation, anxiety, confusion, depression, emotional lability, hallucinations, hyperkinesia, hypoesthesia, hypokinesia, paresthesia, speech disorder, stupor, thinking abnormality, tremor, and vertigo have been reported in less than 1% of patients.[Ref]
Genitourinary side effects have included vaginitis and leukorrhea in up to 3% of patients. Albuminuria, balanitis, dysuria, hematuria, impotence, polyuria, urethral pain, uricaciduria, urinary frequency, urinary tract disorder, impaired urination, urine abnormality, and vulvovaginal disorder have been reported in less than 1% of patients.[Ref]
Dermatologic side effects have included pruritus and rash in 1% to 2% of treated patients. Acne, alopecia, dry skin, epidermal necrolysis, exfoliative dermatitis, fungal dermatitis, herpes simplex, macropapular rash, skin disorder, sweating, urticaria, and vesiculobullous rash have been reported in less than 1% of patients.[Ref]
Non-specific side effects have included asthenia and pain in 1% to 2% of treated patients. Back pain, body odor, chest pain, chills, facial edema, fever, malaise, neck rigidity, and pelvic pain have been reported in less than 1% of treated patients.[Ref]
Cardiovascular side effects have included arrhythmia, hypotension, palpitations, peripheral vascular disorder, postural hypotension, syncope, tachycardia, and vasodilation in less than 1% of patients.[Ref]
Hematologic side effects have been reported in less than 1% of patients and have included anemia, eosinophilia, hypochromic anemia, leukocytosis, leukopenia, lymphadenopathy, lymphocytosis, lymphoma-like reaction, decrease in prothrombin, increase in prothrombin, reticuloendothelial hyperplasia, thrombocytopenia, and increased thromboplastin.[Ref]
Metabolic side effects have included dehydration, edema, electrolyte abnormality, gout, hyperglycemia, hyperlipidemia, hypernatremia, hyperuricemia, peripheral edema, and weight loss in less than 1% of patients.[Ref]
Musculoskeletal side effects have been reported in less than 1% of patients and have included arthralgia and myalgia.[Ref]
Respiratory side effects have included asthma, atelectasis, bronchitis, dyspnea, epistaxis, hemoptysis, increased cough, laryngismus, pharyngitis, pleural effusion, rhinitis, and increased sputum in less than 1% of patients.[Ref]
1. "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.
2. Lode H, Vogel F, Elies W "Grepafloxacin: A review of its safety profile based on clinical trials and postmarketing surveillance." Clin Ther 21 (1999): 61-74
3. Hook EW 3rd, McCormack WM, Martin D, Jones RB, Bean K, Maroli AN "Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men. The STD Study Group." Antimicrob Agents Chemother 41 (1997): 1843-5
4. "New oral fluoroquinolone marketed." Am J Health Syst Pharm 55 (1998): 20
5. Goldstein EJ "Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU 6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety." Clin Infect Dis 23 Suppl 1 (1996): s25-30
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.